Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Increased Eligibility for Attempting Treatment-Free Remission (TFR) with Frontline Nilotinib (NIL) vs Imatinib (IM) in Patients with Philadelphia Chromosome-Positive (Ph+) Chronic Myeloid Leukemia (CML): Results of a Stochastic Simulation Model

Francois-Xavier Mahon, MD PhD Professor, An Tran-Duy, Raechelle G. Ocampo, David Ray, PharmD, MBA, Estella Mendelson, BSRN, MBA, Aby Buchbinder, Pascal Edrich, Sonya J. Snedecor, PhD, Giuseppe Saglio

Blood (2015) 126 (23): 5154.

https://doi.org/10.1182/blood.V126.23.5154.5154

Published: 2015

Journal Articles

Early Molecular Response (EMR) with Frontline Treatment Is a Significant Predictor of Long-Term BCR-ABL Transcript Levels in Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia (CML) in Chronic Phase

Giuseppe Saglio, Sonya J. Snedecor, PhD, Xiang Ji, Ming-Hui Tai, BPharm, MHPA, PhD, David Ray, PharmD, MBA, Estella Mendelson, BSRN, MBA, Aby Buchbinder, Pascal Edrich, Francois-Xavier Mahon, MD PhD Professor

Blood (2015) 126 (23): 1579.

https://doi.org/10.1182/blood.V126.23.1579.1579

Published: 2015

Journal Articles

Association of Mannose Binding Lectin (MBL-2) Deficiency with Pulmonary Infection after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT).

Dick Chung, Lily Ding, Isabelle Amigues, Katuna Kadeishvili, Theresa Lo, Eric Pamer, Stacey Kalambakas, MD, Aby Buchbinder, MD, Genovefa Papanicolaou

Blood (2008) 112 (11): 2209.

https://doi.org/10.1182/blood.V112.11.2209.2209

Published: 2008

Journal Articles

Mannose-Binding Lectin Deficiency - a Risk Factor for Invasive Aspergillosis in Immunocompromised Patients.

Jonathan Lambourne, MD, BA, MRCP, Dan Agranoff, PhD, FRCP, Aby Buchbinder, MD, Peter F Troke, PhD, Raoul Herbrecht, MD, Jodi Lindsay, BSc, MSc, PhD, Thomas Harrison, MD, MPH, FRCP

Blood (2008) 112 (11): 1465.

https://doi.org/10.1182/blood.V112.11.1465.1465

Published: 2008

Journal Articles

Evaluation of Ethnic Differences in Mannose-Binding Lectin (MBL) Level or MBL Genotype.

Aby Buchbinder, MD, CM, Thomas Basile, BS, Cliff Ding, PhD, Jeff Hester, PhD, Jing Yu, MS, Thomas Eckhardt, Dr sc nat, Charles Conover, PhD, MBA, Ivan Horak, MD

Blood (2006) 108 (11): 3859.

https://doi.org/10.1182/blood.V108.11.3859.3859

Published: 2006

Journal Articles

Ig V Gene Mutation Status and CD38 Expression As Novel Prognostic Indicators in Chronic Lymphocytic Leukemia: Presented in part at the 40 th Annual Meeting of The American Society of Hematology, held in Miami Beach, FL, December 4-8, 1998.

Rajendra N. Damle, Tarun Wasil, Franco Fais, Fabio Ghiotto, Angelo Valetto, Steven L. Allen, Aby Buchbinder, Daniel Budman, Klaus Dittmar, Jonathan Kolitz, Stuart M. Lichtman, Philip Schulman, Vincent P. Vinciguerra, Kanti R. Rai, Manlio Ferrarini, Nicholas Chiorazzi

Blood (1999) 94 (6): 1840–1847.

https://doi.org/10.1182/blood.V94.6.1840

Published: 1999

NARROW

Increased Eligibility for Attempting Treatment-Free Remission (TFR) with Frontline Nilotinib (NIL) vs Imatinib (IM) in Patients with Philadelphia Chromosome-Positive (Ph+) Chronic Myeloid Leukemia (CML): Results of a Stochastic Simulation Model

Early Molecular Response (EMR) with Frontline Treatment Is a Significant Predictor of Long-Term BCR-ABL Transcript Levels in Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia (CML) in Chronic Phase

Association of Mannose Binding Lectin (MBL-2) Deficiency with Pulmonary Infection after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT).

Mannose-Binding Lectin Deficiency - a Risk Factor for Invasive Aspergillosis in Immunocompromised Patients.

Evaluation of Ethnic Differences in Mannose-Binding Lectin (MBL) Level or MBL Genotype.

Ig V Gene Mutation Status and CD38 Expression As Novel Prognostic Indicators in Chronic Lymphocytic Leukemia: Presented in part at the 40 th Annual Meeting of The American Society of Hematology, held in Miami Beach, FL, December 4-8, 1998.

Email alerts

ASH Publications

American Society of Hematology

Increased Eligibility for Attempting Treatment-Free Remission (TFR) with Frontline Nilotinib (NIL) vs Imatinib (IM) in Patients with Philadelphia Chromosome-Positive (Ph+) Chronic Myeloid Leukemia (CML): Results of a Stochastic Simulation Model

Early Molecular Response (EMR) with Frontline Treatment Is a Significant Predictor of Long-Term BCR-ABL Transcript Levels in Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia (CML) in Chronic Phase

Association of Mannose Binding Lectin (MBL-2) Deficiency with Pulmonary Infection after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT).

Mannose-Binding Lectin Deficiency - a Risk Factor for Invasive Aspergillosis in Immunocompromised Patients.

Evaluation of Ethnic Differences in Mannose-Binding Lectin (MBL) Level or MBL Genotype.

Ig V Gene Mutation Status and CD38 Expression As Novel Prognostic Indicators in Chronic Lymphocytic Leukemia: Presented in part at the 40 th Annual Meeting of The American Society of Hematology, held in Miami Beach, FL, December 4-8, 1998.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only